A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report

Documenti analoghi

• Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
  di: Kejing Tang, et al.
  Pubblicazione: (2019-02-01)
• A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report
  di: Sun, Yanwei, et al.
  Pubblicazione: (2020)
• Identification of Candidate Biomarkers for EGFR-T790M Drug-resistant 
Gene Mutation in Advanced Lung Adenocarcinoma
  di: Lijuan CHEN, et al.
  Pubblicazione: (2020-11-01)
• Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.
  di: Piotrowska, Zofia, et al.
  Pubblicazione: (2018)
• Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
  di: Saad N, et al.
  Pubblicazione: (2017-03-01)